Papel de los bloqueadores beta en la enfermedad cardiovascular en 2019-Reference-Cited by-同舟云学术

Papel de los bloqueadores beta en la enfermedad cardiovascular en 2019

Published:2019-10 Issue:10 Volume:72 Page:844-852
ISSN:0300-8932
Container-title:Revista Española de Cardiología
language:es
Short-container-title:Revista Española de Cardiología

Author:

Martínez-Milla Juan,Raposeiras-Roubín Sergio,Pascual-Figal Domingo A.,Ibáñez Borja

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference76 articles.

1. The swing of β-blockers;Ibáñez;J Am Coll Cardiol.,2017

2. Writing Committee Members, Yancy CW, Jessup M, et al.; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: A report of the American college of cardiology foundation/american heart association task force on practice guidelines. J Am Coll Cardiol. 2013;62:e147-239.

3. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

4. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS);Flather;Eur Heart J.,2005

5. Beta-Blocker Evaluation of Survival trial investigators; Eichhorn EJ, Domanski MJ, Krause-Steinrauf H, Bristow MR, Lavori PW. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 2001;344:1659-1667.

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 2024 ESC Guidelines for the management of chronic coronary syndromes;European Heart Journal;2024-08-30

2. Development of the first Iranian clinical practice guidelines for the diagnosis, treatment, and secondary prevention of acute coronary syndrome;Journal of Research in Medical Sciences;2024-05

3. Modulation of cAMP/cGMP signaling as prevention of congenital heart defects in Pde2A deficient embryos: a matter of oxidative stress;Cell Death & Disease;2024-02-23

4. Beta-blocker therapy among patients with heart failure;Pathophysiology, Risk Factors, and Management of Chronic Heart Failure;2024

5. The β-Blocker Carvedilol and Related Aryloxypropanolamines Promote ERK1/2 Phosphorylation in HEK293 Cells withK_AValues Distinct From Their Equilibrium Dissociation Constants asβ₂-Adrenoceptor Antagonists: Evidence for Functional Affinity;Journal of Pharmacology and Experimental Therapeutics;2023-12-21